Abstract: The present invention relates to the use of at least one Lactobacillus bacterium, or a composition comprising thereof or conditioned thereby, for decreasing a population of Bilophila wadsworthia or inhibiting the growth thereof

Abstract: The present invention relates to a composition comprising a given Lactobacillus rhamnosus strain and a given Lactobacillus paracasei strain wherein the ratio of said given Lactobacillus rhamnosus strain to said given Lactobacillus paracasei strain (LR?:LP?) is higher or equal to 8:1.

Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: The present invention relates to the preventive or curative treatment of metabolic syndrome and the associated disorders with AhR agonist or microorganism producing AhR agonist.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Abstract: The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.

Abstract: The invention relates to a novel bacterial strain deposited with the CNCM under number 1-4969. This strain has properties that are useful in the treatment of respiratory disorders. The invention also relates to compositions and uses of said strain.

Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Abstract: The present invention relates to a composition comprising a therapeutically effective amount of Bacteroides thetaiotaomicron or an extract thereof for use in the prevention or treatment of an infection in a subject who is immunodepressed, who is immunosuppressed, who has an immature immune system, and/or who has a weakness, and in which the composition comprises at most six species of bacteria and/or extracts thereof. The infections concerned are mainly intestinal infections, in particular those which affect non-human mammals and/or humans.

Abstract: A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and/or by said vector.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.

Abstract: A polypeptide including or consisting of the amino acid sequence SEQ ID NO: 1, for use in the treatment or prevention of an inflammatory disease. A nucleic acid sequence encoding the polypeptide, a vector including the nucleic acid and a host cell including the nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease are also described. A pharmaceutical composition including the polypeptide, the nucleic acid sequence, the vector or the host cell and a pharmaceutically acceptable carrier, for the treatment of inflammatory disease are also disclosed.

Abstract: The invention relates to prokaryotic expression cassettes comprising a stress-regulated promoter, the promoter of the GroESL operon of Lactococcus lactis. Said cassettes can be used for the expression of genes of interest in gram-positive bacteria, and especially for producing and releasing a protein of interest when the bacteria are administered to an individual.

Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.

Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.

Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.